Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis-Reference-Cited by-同舟云学术

Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis

Published:2020-01 Issue:1 Volume:55 Page:105852
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Borjan Jovan,Meyer Kevin A.,Shields Ryan K.,Wenzler Eric

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference31 articles.

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2013. Available fromhttp://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed January 26 2015.

2. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection;Hirsch;J Antimicrob Chemother,2010

3. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia;Shields;Antimicrob Agents Chemother,2017

4. Colistin vs. ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae;van Duin;Clin Infect Dis,2018

5. Combination versus monotherapy for the treatment of infections due to carbapenem-resistant Enterobacteriaceae;Carrara;Curr Opin Infect Dis,2018

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases–co-producing carbapenem-resistant Enterobacter cloacae complex;European Journal of Clinical Microbiology & Infectious Diseases;2024-05-03

2. PAM-1: an antimicrobial peptide with promise against ceftazidime-avibactam resistant Escherichia coli infection;Frontiers in Microbiology;2024-04-30

3. Activities of aztreonam in combination with several novel β-lactam-β-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae strains coproducing KPC and NDM;Frontiers in Microbiology;2024-03-05

4. In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review;Frontiers in Medicine;2023-09-04

5. Synergy with farnesol rejuvenates colistin activity against Colistin-resistant Gram-negative bacteria in vitro and in vivo;International Journal of Antimicrobial Agents;2023-09